ABSTRACT: Although the growth and proliferation of most tumors is fueled by glucose, some tumors are more likely to metabolize glutamine.
■ INTRODUCTION
In the past two decades, the use of 2-[
18 F]fluoro-2-deoxy-Dglucose (FDG) and positron emission tomography (PET) has achieved widespread acceptance as an effective tool for detecting cancers with high rates of glycolysis. It is generally accepted that a high rate of glucose metabolism (Warburg effect) is associated with changes in tumor-driven alternative gene expression. 1, 2 However, despite the tremendous promise of FDG-PET for detecting and monitoring tumor metabolism, a significant portion of malignant tumors are not FDG-positive and can be missed in a FDG-PET scan. Accordingly, there is a clear and urgent need to develop additional metabolic tracers, particularly for cancers with low FDG-uptake.
Recent reports suggest that metabolic reprogramming may cause some cancers to switch their energy source from glucose to glutamine. 3−6 These tumors could be imaged with 18 Flabeled glutamine tracers. 7−9 Glutamine, which is found circulating in the blood and is also concentrated in the skeletal muscles (0.5−1 mmol/L), has various critical functions: as a substrate for DNA and protein synthesis, a primary source of fuel for cells lining the inside of the small intestine and rapidly dividing immune cells, and as a regulator of acid−base balance by producing ammonium in the kidneys. Enhanced glutamine utilization in cancers due to changes in the expression of oncogenic signaling pathways can lead to glutaminolysis. In these cases, blocking glutamine synthetic pathways may lead to tumor cell death. 10 Glutamine imaging agents may be useful for testing the therapeutic efficacy of antitumor agents aimed at reducing glutamine metabolism in tumors.
In order to study glutamine metabolizing tumors, we previously prepared and tested L-5-[ 11 C] glutamine. 7 In tumor cell uptake studies, the maximum uptake of L-5-[ spontaneous mammary gland tumors showed prominent tumor uptake and retention. The results suggested that L-5-[
11 C]-glutamine would be useful for probing in vivo tumor metabolism in glutaminolytic tumors. 7 Because 11 C has a half-life of 20 min, it would not be practical for most clinical settings. To make an imaging agent that would be better for clinical use, we created an alternative metabolic tracer labeled with 18 F, which has a half-life of 110 min. In vitro studies with [ 18 F](2S,4R)-4-fluoroglutamine, 2 ([ 18 F](2S,4R)-4-FGln) showed that both 9L and SF188 tumor cells displayed a high rate of glutamine uptake (maximum uptake ≈16% dose/ 100 μg protein), and the radioactivity trapped inside the cell was associated with the macromolecular fraction precipitated by trichloroacetic acid (TCA). The cell uptake of [ 18 F](2S,4R)-4-FGln, 2, by SF188 cells is comparable to that of [ 3 H]Lglutamine but higher than that of FDG. Biodistribution and PET imaging studies showed that [ 18 F](2S,4R)-4-FGln, 2, localized in tumors with a higher uptake than that of surrounding muscle and liver tissues, suggesting that [ 18 F]-(2S,4R)-4-FGln, 2, is selectively taken up and trapped by the tumor cells. 8, 9 One of the drawbacks of [ 18 F](2S,4R)-4-FGln, 2, (and its related optical isomers) is the radiolabeling reaction, which is relatively difficult and prone to formation of stereoisomers due a secondary fluorination reaction. 9 To avoid this complication, we have designed and tested [ 
. The 4-(3-fluoropropyl)glutamines contain an extended propyl group. This will make it easier for the SN 2 fluorine substitution with a good leaving group (OTs) used in the labeling reaction. To preserve the amide functional group at the C5 position, we have synthesized two types of precursors suitable for radiolabeling (fluoro for tosylate substitution reaction). Reported herein is the preparation and in vitro and in vivo studies of these glutamine analogs.
■ EXPERIMENTAL SECTION
General Information. All reagents used were commercial products and were used without further purification unless otherwise indicated. Boc-Glu(OBzl)−OH (Boc-L-glutamic acid 5-benzyl ester, 15) was purchased from Sigma-Aldrich. Flash chromatography (FC) was performed using silica gel 60 (230− 400 mesh, Sigma-Aldrich). 1 H NMR spectra were obtained at 200 MHz and 13 C NMR spectra were recorded at 50 MHz (Bruker DPX 200 spectrometer). Chemical shifts are reported as δ values (parts per million) relative to remaining protons in deuterated solvent. Coupling constants are reported in hertz. The multiplicity is defined by s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), br (broad), or m (multiplet). HPLC analyses were performed on an Aglient LC 1100 series. High-resolution MS experiments were performed using an Agilent Technologies LC/MSD TOF mass spectrometer. Syntheses. Compounds 5−8 were synthesized according to the procedures reported previously. 9 (S)-tert-Butyl 2-(tert-butoxycarbonylamino)-4-(tosyloxy) Butanoate (9) . To a solution of compound 8 (554 mg, 2 mmol) in 10 mL of dry dichloromethane (DCM) was added Et 3 N (1.4 mL, 10 mmol), 4-(dimethylamino)pyridine (DMAP, 24 mg, 0.2 mmol), and p-toluenesulfonyl chloride (TsCl, 764 mg, 4 mmol) at 0°C. The mixture was stirred at room temperature (rt) overnight. Ice-cold water (15 mL) was poured into the reaction mixture and the mixture was extracted with DCM (15 × 3 mL), the combined organic layer was dried with magnesium sulfate (MgSO 4 ) and was purified with flash chromatography (FC, EtOAc/hexane = 2/8) to give 739.6 mg colorless oil 9 (yield: 86.1%). 1 (10) . Sodium iodide (240 mg, 1.6 mmol) was added to a solution of compound 9 (343 mg, 0.8 mmol) in 10 mL of acetone (HPLC grade) at rt. The mixture was stirred at 60°C for 3 h. The solvent was then removed and the residue was dissolved in 15 mL of DCM. The precipitated solid was filtered out and filtrate was concentrated. N,N-Dimethylformamide (DMF, 7 mL) and potassium cyanide (78 mg, 1.2 mmol) were added to the residue. The mixture was stirred at rt overnight. The reaction mixture was quenched with 25 mL of ethyl acetate and was washed with H 2 O (10 × 3 mL). The organic layer was dried over MgSO 4 (2S,4S)-tert-Butyl 2-(tert-Butoxycarbonylamino)-4-cyano-7-(tosyloxy)heptanoate (13a) and (2S,4R)-tert-Butyl 2-(tertButoxycarbonylamino)-4-cyano-7-(tosyloxy)heptanoate (13b). To a solution of compound 12a (137 mg, 0.4 mmol) in 7 mL of DCM was added Et 3 N (0.3 mL, 2.1 mmol) and DMAP (5 mg, 0.04 mmol) at°C, followed by TsCl (153 mg, 0.8 mmol). The resulting mixture was stirred at 0°C for 1 and 24 h at rt. The reaction was quenched with 15 mL of water and extracted with DCM (10 × 3 mL). The organic layer was dried over MgSO 4 (16) . To a solution of Boc-Glu(OBzl)−OH, 15, (3.37 g, 10 mmol) in 20 mL of DCM was added tert-butyl 2,2,2-trichloroacetimidate (3.9 g, 18 mmol) in 20 mL of cyclohexane dropwise. The mixture was stirred at rt for 5 min. BF 3 ·Et 2 O (0.12 mL, 1 mmol) was added dropwise. The reaction mixture was stirred at rt for 4 h. The solid was filtered off. The filtrate was evaporated in vacuo and the residue was purified by FC (EtOAc/hexanes = 2/8) to give 3 g of white solid 16 (yield: 76.3%). (18) . To a solution of compound 17 (860 mg, 2 mmol) in 7 mL of THF was added 9-BBN (8 mL, 0.5 M solution in THF) dropwise at 0°C. After stirring at 0°C for 1 h, the reaction mixture was moved to rt and stirred for another 48 h. The mixture was then cooled in an ice-bath. H 2 O 2 (2.2 mL of 30 wt % solution in H 2 O) and NaOH (3 mL, 1 M) were added dropwise. The mixture was stirred at rt for 30 min, diluted with of 15 mL H 2 O, and extracted with ethyl acetate. The organic layer was dried over MgSO 4 and filtered. The filtrate was concentrated, and the residue was purified by FC (EtOAc/hexane = 1/1) to give 700 mg of colorless oil 18 (yield: 77.4%). (19) . To a solution of compound 18 (530 mg, 1.2 mmol) in 10 mL of DCM was added 3,4-dihydro-2H-pyran (225 μL, 2.4 mmol) and pyridinium p-toluenesulfonate (30 mg, 0.12 mmol). The mixture was stirred at rt for 3 h. The solvent was evaporated in vacuo and the residue was purified by FC (EtOAc/hexanes = 3/7) to give 578 mg of colorless oil 19 (yield: 90%). (2S,4S)-tert-Butyl 2-(tert-Butoxycarbonylamino)-7-hydroxy-4-(2,4,6-trimethoxybenzylcarbamoyl)heptanoate (21) . To a solution of compound 20 (534 mg, 1.2 mmol) in 2 mL of DCM and 2 mL of DMF was added Et 3 N (1.9 mmol, 0.26 mL), HOBt (1.44 mmol, 297 mg), 2,4,6-trimethoxybenzylamine hydrochloride (370 mg, 1.58 mmol), and N,Ndicyclohexylcarbodiimide (276 mg, 1.8 mmol) at 0°C. The mixture was stirred at rt for 24 h. A total of 30 mL of EtOAc was added to the reaction mixture. The mixture was then washed with citric acid (10% in H 2 O, 5 mL), H 2 O (5 mL × 2) as well as brine (5 mL), dried over Na 2 SO 4 , and filtered. The filtrate was concentrated to give 624 mg of oil. The residue was dissolved in 4 mL of EtOH. Pyridinium p-toluenesulfonate (50 mg, 0.2 mmol) was then added. After heating at 50°C for 4 h, the solvent was evaporated in vacuo and the residue was purified by FC (EtOAc/hexanes = 3/7) to give 203 mg of colorless oil 21 (yield: 30.8%). (24) . To a solution of tris(dimethylamino)sulfonium difluorotrimethylsilicate (1.31 g, 4.75 mmol) in 5 mL of THF and 5 mL of DMF was added Et 3 N(HF) 3 (0.273 mL) dropwise followed by 23 (0.700 g, 1.16 mmol) in 5 mL of THF. The mixture was then heated at 45°C overnight. The reaction was quenched by the addition of icecold water (5 mL) and diluted with 100 mL of EtOAc, then washed with H 2 O (25 mL × 2) and brine (25 mL (25) . A mixture of the ester 24 (0.430 g, 0.95 mmol) and 10% Pd/C (0.100 g) in absolute EtOH (10 mL) was stirred under hydrogen overnight. This mixture was then filtered, and the filtrate was concentrated under vacuum to give 0.345 g of colorless oil 25 (yield: 100%). 45 mmol) at 0°C. The solution was allowed to warm to rt. After stirred overnight, the mixture was diluted with 150 mL to EtOAc and washed with H 2 O (30 mL × 2) and brine (30 mL The radiosynthesis was performed by a similar method as described previously. 9 Briefly, an activated SepPak Light QMA Carb was loaded with [
18 F]fluoride (740 to 1480 MBq (20 to 40 mCi)) and eluted with 1 mL of 18-crown-6/KHCO 3 (160 mg of 18-crown-6 in 18.6 mL of ACN/29 mg of KHCO 3 in 3.4 mL of water). The solution was blown with argon until dry and dried twice azeotropically with 1 mL of acetonitrile at 80°C under a flow of argon. The dried [
18 F]fluoride was cooled in an ice bath and 5 mg of tosylate precursor (O-tosylate, 13a and 13b, respectively) was dissolved in 0.5 mL of DMSO and added to the dried [
18 F]fluoride. The mixture was heated for 10 min at 110°C in an oil bath. The mixture was then cooled in an ice bath and added to 6 mL of water/1 mL of acetonitrile. The mixture was loaded onto an activated Oasis HLB 3 cm 3 cartridge, pushed through, and washed twice with 3 mL of water. The desired radiolabeled compound was eluted with 1 mL of acetonitrile. The acetonitrile solution was blown until dry. A mixture of 400 μL of TFA/100 of μL concentrated H 2 SO 4 was added and heated for 10 min at 120°C in a capped 10 mL vial. TFA was removed under argon while still warm. The reaction tube was then cooled in an ice bath. Water (1 mL) was slowly added and the mixture was neutralized by the slow addition of a saturated Na 2 CO 3 solution under heavy shaking (∼1000 μL) (pH ∼ 8). The mixture was put through an activated Oasis HLB 3 cm Alternatively, TmobNH precursor, 22, was used under a similar labeling condition as described above (18-crown-6/ KHCO 3 /ACN/80°C/20 min). It was found that the TmobNH intermediate, 26, was formed with a lower yield of 6.6 ± 1.6%, radiochemical purity 98% (n = 3). The 18 F intermediate, [ and Mg 2+ ). After washing with ice-cold PBS, 350 μL of 0.1 N NaOH was used to lyse the cells. The lysed cells were collected onto filter paper and counted together with samples of the incubation dose using a gamma counter (Packard Cobra). After 24 h, 3 H activity was counted using a scintillation counter (Beckman LS 6500). A total of 100 μL of the cell lysate was used to determine the protein concentration (Modified Lowry Protein Assay). The data was normalized as percentage uptake of initial dose (ID) relative to 100 μg of protein content (% ID/100 μg of protein To identify the ligand's stability in supernatant after precipitation with trichloroacetic acid (TCA), cells were grown in 10 cm dishes and incubated with 1.8 MBq [
18 F](2S,4S)-4-FPGln, 4, only. At the end of incubation, the radioactive medium was removed, the cells were washed three times with ice cold PBS without Ca 2+ and Mg 2+ , treated with 0.25% trypsin, and resuspended in PBS. The samples were centrifuged (18 000g, 3 min), the supernatant removed, and the cells were suspended in 200 μL and 1% Triton-X 100 (Sigma, St. Louis, MO). After vortexing, 800 μL of ice cold 15% TCA was added to the solution. After precipitating for 10 min, the cells were centrifuged again (18 000g, 3 min) and washed twice with 15% ice cold TCA. The radioactivity of both gamma-and beta-emitting isotopes was determined separately for the supernatant and pellet. Protein incorporation was calculated as a percentage of acid precipitable activity.
In Vitro Transport Characterization Studies (Inhibition Studies). To characterize the transport of [ 18 F](2S,4S)-4-FPGln, 4, competitive inhibition studies were conducted using the 9L cell line. The tracer was incubated at 37°C for 30 min. The cells were processed as described above. Various inhibitors were then added to the cells in concentrations ranging from 0.1 to 5 mM in PBS solution. Selected inhibitors included synthetic amino acid transport inhibitors such as Nmethyl-α-aminoisobutyric acid (MeAIB) for system A, and 2-amino-bicylo[2.2.1] heptane-2-carboxylic acid (BCH) for system L.
11−13 Natural amino acids, such as L-serine and Lglutamine, were also used as inhibitors, although they are not specific for a particular amino acid transport system. The data was compared in reference to uptake of 8 F344 rats were purchased from Charles River Laboratories (Malvern, PA). 9L tumor cells (∼10 6 ) in PBS (0.2 mL) were injected subcutaneously into the lower right flank of the rat. The tumors took 12−15 days to reach appropriate size (1 cm diameter). All animals were fasted for 12−18 h prior to the study. Six rats per group were used for the biodistribution study. The rats were anesthetized with isoflurane (2−3%) and 0.2 mL of saline solution containing 25 μCi of the ligand was injected intravenously. The rats were sacrificed at 30 and 60 min postinjection by cardiac excision while under isoflurane anesthesia. The organs of interest were removed, weighed, and the radioactivity was counted with a gamma counter (Packard Cobra). The percent dose per gram 8 All scans were performed on a dedicated animal PET scanner (Mosaic by Phillips) that has a field of view of 11.5 cm. F344 rats with 9L tumors were used for the imaging studies. A total of 22−37 MBq of activity was injected intravenously via the lateral tail vein. All animals were sedated with isoflurane anesthesia (2−3%, 1 L/min oxygen) and were then placed on a heating pad in order to maintain body temperature throughout the procedure. The animals were visually monitored for breathing and any other signs of distress throughout the entire imaging period. The data acquisition began after an intravenous injection of the tracer. All scans were conducted over a period of 120 min (dynamic, 5 min/frame). The frames were reconstructed and then analyzed with AMIDE imaging analysis software.
■ RESULTS

Synthesis.
In order to produce , we employed two different schemes (Schemes 1 and 2) for preparation of nonradioactive "cold" compounds (3 and 4) and the cyanide and -OTs precursors for radiolabeling. One approach was to prepare the corresponding protected 4-cyanide derivatives, which led to the formation of the desired final products. Commercially purchased Boc-Asp(OBzl)−OH, 5, was treated with tert-butyl 2,2,2-trichloroacetimidate/BF 3 ·Et 2 O at room temperature to give the t-BuO-ester, 6; the BnO-ester group was converted to the acid, 7, by Pd/C catalyzed hydrogenation. The aspartic acid, 7, was carefully reduced with NaBH 4 in THF/water at −15 to 0°C to the corresponding alcohol, 8. The alcohol group was successfully converted to the cyanide, 10, through the -OTs intermediate, 9. The cyanide derivative, 10, was treated with LiHMDS and allyl bromide at −78°C to give (2S,4S)-tert-butyl 2-(tert-butoxycarbonylamino)-4-cyanohept-6-enoate (11a) and (2S,4R)-tert-butyl 2-(tertbutoxycarbonylamino)-4-cyanohept-6-enoate (11b) (11a to 11b ratio of 2:1 in 28% and 15% isolated yields). A similar reaction was reported previously for preparation of allyl derivatives of aspartate using the dianionic allylation reactions of amino acid derivatives. 14 The allyl derivatives, 11a and 11b, were separated and purified by flash chromatography. They were converted to the corresponding alcohols, 12a and 12b, and following the treatment with tosyl chloride to the Otosylated 13a and 13b in good yields. The O-tosylated 13a and 13b were treated with TASF, Et 3 N(HF) 3 , DCM, DMF, 50°C, overnight to give the desired 14a and 14b, in good yields. Optimization of the fluorination reaction condition using TASF and Et 3 N(HF) 3 , as the reagents was reported previously for the preparation of 4-fluoroglutamine. 9 Deprotection using hydrochloric acid at room temperature produced the final end products, The second method introduced N-Tmob protected precursors (as a protecting group to preserve the amide) for radiolabeling and deprotection. Previously, we have tested for the preparation of N-Tmob protected precursors for making isomers of 4-fluoroglutamine (4-FGln). 9 We successfully developed 18 F labeling using this precursor under different labeling conditions. We wanted to extend the same method to the synthesis and labeling of [ . To achieve this, we started with commercially available, Boc-Glu(OBzl)−OH, 15. After treating with tertbutyl 2,2,2-trichloroacetimidate/BF 3 ·Et 2 O at room temperature, it gave the t-Bu ester, 16. Using the same dianionic allylation reactions of amino acid derivatives, 14 the reaction preferentially produced the protected (2S,4S)-4-allyl-glutamate (in 58% yield). It is interesting to note that the reaction led to the (2S,4S) isomer only. The allyl group was converted to alcohol, 18, by 9-BBN/H 2 O 2 /NaOH in 0°C. The alcohol was protected by THP, and the O-benzyl ester was hydrolyzed and the acid, 20, was transformed to Tmob-protected amide, 21. The alcohol, 21, was treated with tosyl chloride to the Otosylated, 22, which is a suitable precursor for a radioactive 18 F labeling reaction. In order to provide an authentic sample, a cold standard, for the first step of the radioactive 18 F labeling reaction, we also prepared compound, 26.
To further confirm the chemical structure, a slow evaporating recrystallization method provided excellent crystals of "cold" (2S,4S)-4-FPGln, 4 and the X-ray crystallographic analysis data added support to the structure assignment (Figure 2) . The optically pure (2S,4S)-4-FPGln, 4, has never been prepared and presented before. In the X-ray crystallographic structures of (2S,4R)4F-Gln, 2, and (2S,4S)-4-FPGln, 4, the amino acid groups on the right side of the molecules were comparable, whereas the amide group on the left appeared to be varied and different from each other. The results reported in Figure 2 firmly establish the configuration, which may facilitate future use of other 4-fluoroglutamine isomers for biological and medical applications.
Radiolabeling for 18 F]fluoride using O-tosylated cyanide derivatives, 13a or 13b, was performed with 18-crown-6/KHCO 3 in DMSO at 110°C for 10 min, followed by a solid-phase extraction (Oasis HLB 3 cm 3 cartridge). The intermediate was eluted from this cartridge and treated with H 2 SO 4 /TFA at 120°C for 10 min. The crude labeled products were cooled to room temperature and neutralized with a saturated Na 2 CO 3 solution. The mixture was passed through an Oasis HLB 3 cm 3 cartridge topped with Ag11-A8 resin. The cartridge was eluted with phosphate buffered saline (pH 7.0) to give the desired radioactive Figure 3 .) The decay-corrected radiochemical yield was 6.2 ± 3.9%, radiochemical purity 91.5 ± 1.5%, optical purity >99%, n = 2 (for 3) and 25.2 ± 2.3%, RCP 92.8 ± 2.6%, optical purity >99%, n = 5 (for 4). It is important to note that radiolabeling of these two seemingly close analogs showed very different yields. We noted the disparity in radiolabeling yields, but we do not have a simple explanation for this phenomenon. 9 However, much to our surprise, the radiochemical yield for precursor, 22, gave a lower labeling yield. The decay corrected radiochemical yield was 2.7 ± 0.9%, n = 3.
In Vitro Cell Uptake and Inhibition Study in 9L Tumor Cells. In order to test the specificity of this radiotracer, in vitro cell uptake and inhibition studies were performed in 9L cells. Both Figure 5 suggested that the system A inhibitor, MeAIB (N-methyl-α-aminoisobutyric acid), had no inhibitory effect on the uptake, indicating that the system A amino acid transport was not involved in the uptake of this new tracer. System L inhibitor, BCH (2-aminobicylo[2.2.1] heptane-2-carboxylic acid), System ASC inhibitor L-serine (L-Ser) and System ASC (SLC1A5), N inhibitor, Lglutamine (L-Gln), exhibited similar concentration dependent reduction of cell uptake, thus indicating potential involvement of system L, ASC, and N in the uptake ( Figure 5 ). 
. As these images demonstrate, the 9L tumors could be visualized with either of the ligands. High kidney, liver, and bladder uptake were also observed. Defluorination/bone uptake was more apparent in the images of To assess the in vivo kinetics, region-of-interest analysis was performed (using AMIDE software to generate the time-activity curves; Figures 8  and 9 ). The kinetic curves confirmed that all the tracers exhibited higher tumor uptake compared to the muscle (background) regions. 
■ DISCUSSION
Glutamine is found circulating in the blood as well as stored in skeletal muscles in high concentrations (0.5−1 mmol/L). Glutamine plays various critical functions: as an energy source and a substrate for DNA and protein synthesis, a primary source of fuel for cells lining the inside of the small intestine and rapidly dividing immune cells, and as a regulator of acid− base balance by producing ammonium in the kidneys. In the brain, the glutamine−glutamate shunt is a critical pathway to control the inhibitory and excitatory neuronal signals. Glutamine transporters play an important role in regulating mammalian cell functions. There are three known glutamine transporters, SLC1A5 (ASCT2, Km 20 mM), LAT1 (SLC7A5, Na + independent), SNAT (Na + /neutral transporter). 16−19 In the context of tumor growth, SLC1A5 is the most important glutamine transporter responsible for rapidly growing tumors. In these tumor cells, the expression of SLC1A5 is up-regulated. further evaluate the significance of the observation on different levels of inhibition by LAT vs SLC1A5 subtypes of amino acid transporters.
[ ) was also prepared and tested. 30−32 It was found that 18 F-FSPG, a glutamic acid containing a 3-fluoro-propyl substitution group at the C4 position, showed good tumor uptake and reduced in vivo defluorination. 29 In vivo human studies suggest that 18 F-FSPG is a tracer useful for assessing system xC − (anionic amino acid) transporter activity in tumors with PET. 31, 32 Piramal Biotechnology is now developing the 18 
F-FSPG for imaging tumors in which xC
− transporters are prominently expressed and oxidative stress is up-regulated.
The new (2S,4S)-4-FPGln, 4, reported in this paper, is a structural analog of glutamine containing a 3-fluoro-propyl substitution group at the C4 position. The mechanisms of uptake for [ 18 F](2S,4S)-4-FPGln, 4, are associated with three main amino acid transporters, SLC1A5 (ASCT2), LAT1 (SLC7A5, Na + independent), and SNAT (Na + /neutral transporter). Based on the inhibition studies, it appears that LAT inhibition was the most prominent, suggesting that LAT may be a preferred transporter for (2S,4S)-4-FPGln, 4. For [ 11 C] Gln, 1, and (2S,4R)-4-FGln, 2, the most important amino acid transporter appeared to be SLC1A5 (ASCT2 Further exploration may be needed to clarify the similarities and differences between these probes. For the development of effective probes for studying glutamine metabolism, one should consider more than simple factors, such as tumor cell uptake and in vivo tumor signal localization. It may also be necessary to consider the subsequent intracellular metabolic processes, or the lack thereof. Compared to the "natural" Preliminary human studies have demonstrated that the bone marrow uptake in the vertebral region is relatively low. 31, 32 The same scenario may or may not apply to the second pair of glutamine probes (Figure 10) . We have noticed a reduced bone uptake and good tumor uptake in the rats receiving 8 Loss of fluoride is a constant concern for fluoro-alkyl labeled radiopharmaceuticals. Our observation suggests that defluorination is not an issue for 4.
In summary, a new glutamine analog, [ 18 F](2S,4S)-4-FPGln, 4, has shown tumor specific uptake in vitro and in vivo. However, the tumor uptake and retention mechanisms may be significantly different from other glutamine probes, such as [ 11 
